...
首页> 外文期刊>Cancer Cell >Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
【24h】

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors

机译:组成型和诱导趋化因子之间的合作使得能够在实体肿瘤中进行细胞植入和免疫发作

获取原文
获取原文并翻译 | 示例
           

摘要

We investigated the role of chemokines in regulating T cell accumulation in solid tumors. CCL5 and CXCL9 overexpression was associated with CD8(+) T cell infiltration in solid tumors. T cell infiltration required tumor cell-derived CCL5 and was amplified by IFN-gamma-inducible, myeloid cell-secreted CXCL9. CCL5 and CXCL9 coexpression revealed immunoreactive tumors with prolonged survival and response to checkpoint blockade. Loss of CCL5 expression in human tumors was associated with epigenetic silencing through DNA methylation. Reduction of CCL5 expression caused tumor-infiltrating lymphocyte (TIL) desertification, whereas forced CCL5 expression prevented Cxc/9 expression and TILs loss, and attenuated tumor growth in mice through IFN-gamma. The cooperation between tumor-derived CCL5 and IFN-gamma-inducible CXCR3 ligands secreted by myeloid cells is key for orchestrating T cell infiltration in immunoreactive and immunoresponsive tumors.
机译:我们调查了趋化因子在调节实体肿瘤中的T细胞积累方面的作用。 CCL5和CXCL9过表达与固体瘤中的CD8(+)T细胞浸润有关。 T细胞浸润需要肿瘤细胞衍生的CCl5,并通过IFN-Gamma-Invucible,髓样细胞分泌的CXCl9扩增。 CCL5和CXCL9共表达揭示了免疫反应性肿瘤,延长存活率和对检查点封闭的反应。 人肿瘤中CCL5表达的丧失与通过DNA甲基化的表观遗传沉默有关。 CCL5表达的还原引起肿瘤浸润淋巴细胞(TIL)荒漠化,而强制性的CCL5表达可防止CXC / 9表达和直到损失,并通过IFN-γ在小鼠中减弱肿瘤生长。 髓样细胞分泌的肿瘤衍生的CCL5和IFN-γ-诱导的CXCR3配体的合作是在免疫反应和免疫常用肿瘤中锻炼T细胞浸润的关键。

著录项

  • 来源
    《Cancer Cell》 |2019年第6期|共26页
  • 作者单位

    Univ Lausanne Ludwig Inst Canc Res CH-1066 Lausanne Switzerland;

    Univ Lausanne Ludwig Inst Canc Res CH-1066 Lausanne Switzerland;

    Univ Lausanne Ludwig Inst Canc Res CH-1066 Lausanne Switzerland;

    Univ Lausanne Ludwig Inst Canc Res CH-1066 Lausanne Switzerland;

    Univ Lausanne Ludwig Inst Canc Res CH-1066 Lausanne Switzerland;

    Univ Penn Ovarian Canc Res Ctr Perelman Sch Med Philadelphia PA 19104 USA;

    Univ Lausanne Ludwig Inst Canc Res CH-1066 Lausanne Switzerland;

    Univ Penn Ovarian Canc Res Ctr Perelman Sch Med Philadelphia PA 19104 USA;

    Univ Penn Ovarian Canc Res Ctr Perelman Sch Med Philadelphia PA 19104 USA;

    Ohio Univ Russ Coll Engn &

    Technol Athens OH 45701 USA;

    H Lee Moffitt Canc Ctr &

    Res Inst Dept Immunol &

    Gynecol Oncol Tampa FL 33612 USA;

    SIB Swiss Inst Bioinformat CH-1015 Lausanne Switzerland;

    Univ Penn Perelman Sch Med Dept Pathol &

    Lab Med Philadelphia PA 19104 USA;

    Univ Penn Ovarian Canc Res Ctr Perelman Sch Med Philadelphia PA 19104 USA;

    Univ Penn Perelman Sch Med Dept Biostat &

    Epidemiol Philadelphia PA 19104 USA;

    Univ Penn Ovarian Canc Res Ctr Perelman Sch Med Philadelphia PA 19104 USA;

    Bristol Myers Squibb Princeton NJ 08540 USA;

    NYU Laura &

    Isaac Perlmutter Canc Ctr 522 First Ave Room 1310 Smilow Bldg New York NY 10016 USA;

    Brigham &

    Womens Hosp Dept Pathol 75 Francis St Boston MA 02115 USA;

    Dana Farber Canc Inst Ctr Immunooncol Boston MA 02215 USA;

    Univ Lausanne Ludwig Inst Canc Res CH-1066 Lausanne Switzerland;

    Univ Lausanne Ludwig Inst Canc Res CH-1066 Lausanne Switzerland;

    Univ Penn Ovarian Canc Res Ctr Perelman Sch Med Philadelphia PA 19104 USA;

    Univ Lausanne Ludwig Inst Canc Res CH-1066 Lausanne Switzerland;

    Univ Lausanne Ludwig Inst Canc Res CH-1066 Lausanne Switzerland;

    Univ Lausanne Ludwig Inst Canc Res CH-1066 Lausanne Switzerland;

    Univ Lausanne Ludwig Inst Canc Res CH-1066 Lausanne Switzerland;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号